These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18678315)

  • 41. Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?
    Porapakkham P; Porapakkham P; Krum H
    Cardiovasc Ther; 2010 Apr; 28(2):93-100. PubMed ID: 20398098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure.
    Tatli E; Kurum T; Aktoz M; Buyuklu M
    Int J Cardiol; 2008 Apr; 125(2):273-6. PubMed ID: 18053592
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
    DasGupta P; Lahiri A
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S62-7. PubMed ID: 1378153
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A frequent gene polymorphism affecting the heart-rate response to carvedilol.
    Eschenhagen T
    Pharmacogenomics; 2013 Jan; 14(2):115-8. PubMed ID: 23327570
    [No Abstract]   [Full Text] [Related]  

  • 46. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
    Khattar RS; Senior R; Soman P; van der Does R; Lahiri A
    Am Heart J; 2001 Oct; 142(4):704-13. PubMed ID: 11579363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A fairer comparison between carvedilol and metoprolol is still to be done].
    Johnsson G; Aberg J
    Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018
    [No Abstract]   [Full Text] [Related]  

  • 48. The impact of beta-blockade on mortality rates in patients with congestive heart failure.
    Goldstein S; Gottlieb SS
    J Card Fail; 2000 Jun; 6(2 Suppl 1):15-24. PubMed ID: 10908094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiomyopathy and calciphylaxis in a patient with normal renal function: a case report.
    Kolli S; Douglas J; Doumit E; Guglin M
    Congest Heart Fail; 2010; 16(2):71-2. PubMed ID: 20412472
    [No Abstract]   [Full Text] [Related]  

  • 50. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
    Kojima M; Sato K; Kimura G; Ueda R; Dohi Y
    J Cardiovasc Pharmacol; 2007 Apr; 49(4):191-6. PubMed ID: 17438403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effect of carvedilol on survival in severe chronic heart failure. A trial of the beta-blocker bucindolol in patient with advanced heart failure].
    Bosimini E
    Ital Heart J Suppl; 2001 Aug; 2(8):919-21. PubMed ID: 11582729
    [No Abstract]   [Full Text] [Related]  

  • 52. [Beta receptor blockade in heart failure: a new look at an old topic].
    Klein W
    Wien Med Wochenschr; 1996; 146(5):96-7. PubMed ID: 8686329
    [No Abstract]   [Full Text] [Related]  

  • 53. [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
    Swedberg K
    Lakartidningen; 2003 Sep; 100(37):2852-4. PubMed ID: 14558169
    [No Abstract]   [Full Text] [Related]  

  • 54. Are there clinically important differences between beta-blockers in heart failure?
    Cleland JG; Loh H; Windram J
    Heart Fail Clin; 2005 Apr; 1(1):57-66. PubMed ID: 17386834
    [No Abstract]   [Full Text] [Related]  

  • 55. Sudden cardiac death risk factors in patients with heart failure treated with carvedilol.
    Nessler J; Nessler B; Kitliński M; Libionka A; Kubinyi A; Konduracka E; Piwowarska W
    Kardiol Pol; 2007 Dec; 65(12):1417-22; discussion 1423-4. PubMed ID: 18181053
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
    Cioffi G; De Feo S; Pulignano G; Del Sindaco D; Tarantini L; Stefenelli C; Opasich C
    Int J Cardiol; 2006 Feb; 107(2):220-4. PubMed ID: 16412800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Severe heart failure. Carvedilol lowers mortality].
    MMW Fortschr Med; 2001 Mar; 143(9):58. PubMed ID: 11288541
    [No Abstract]   [Full Text] [Related]  

  • 58. Beta-blockers in heart failure: how far have we progressed?
    Adams KF
    Postgrad Med; 2002 Nov; 112(5 Suppl Unanswered):7-15. PubMed ID: 19667603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Carvedilol in ischemic heart failure. Hibernating myocardium resuscitated].
    MMW Fortschr Med; 2003 Feb; 145(8):57. PubMed ID: 12661451
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of congestive heart failure. Has the time come for decreased complexity?
    Rydén L; Remme WJ
    Eur Heart J; 1999 Jun; 20(12):867-71. PubMed ID: 10329091
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.